Literature DB >> 8887934

Elevated serum angiotensin-converting enzyme activity in onchocerciasis.

M J Ronday1, A Van der Lelij, M Wienesen, A Rothova, J S Stilma, A Kijlstra.   

Abstract

Our objective was to measure serum angiotensin-converting enzyme (ACE) activity in patients with onchocerciasis. Serum ACE activity is commonly used in the diagnosis and follow-up of patients with sarcoidosis. However, serum ACE activity can also be elevated in a number of other granulomatous disorders. In onchocerciasis, a parasitic disease affecting millions of people in Africa and Central and South America, granulomatous tissue around adult worms has been identified, yet raised serum ACE activity has not been reported so far. We measured serum ACE activity in serum samples from 42 onchocerciasis patients and 39 endemic controls previously enrolled in two studies concerning the side effects after invermectin treatment in Sierra Leone, West Africa. The mean ACE activity in the patient group was 53.8 units/liter (S.D. 19.8) compared with 35.2 units/liter (S.D. 14.0) in the control group (p < 0.0001). Nine of 42 patients had elevated ACE activity (mean of the endemic controls +/- 2 S.D.) compared with 1 of 39 controls (p = 0.01). Sensitivity and specificity of elevated ACE in serum from onchocerciasis patients from Sierra Leone was 21 and 97%, respectively. ACE activity was not related to the microfilarial skin load or development of side effects after ivermectin treatment. Serum ACE activity can be elevated in onchocerciasis. Clinicians should be aware of this phenomenon when determining serum ACE activity in persons from endemic areas.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8887934     DOI: 10.1007/bf00164636

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  9 in total

1.  A sensitive fluorimetric assay for serum angiotensin-converting enzyme.

Authors:  J Friedland; E Silverstein
Journal:  Am J Clin Pathol       Date:  1976-08       Impact factor: 2.493

2.  Neutrophil activation in ivermectin-treated onchocerciasis patients.

Authors:  F L Njoo; C E Hack; J Oosting; J S Stilma; A Kijlstra
Journal:  Clin Exp Immunol       Date:  1993-11       Impact factor: 4.330

3.  Onchocerca volvulus and Schistosoma haematobium infection in southern Sierra Leone.

Authors:  J C Porter; J A Whitworth
Journal:  Lancet       Date:  1994-12-03       Impact factor: 79.321

4.  Angiotensin converting enzyme. V. Serum levels as monitors of disease activity in corticosteroid-treated sarcoidosis.

Authors:  C Grönhagen-Riska; O Selroos; M Niemistö
Journal:  Eur J Respir Dis       Date:  1980-04

5.  Side-effects of ivermectin in treatment of onchocerciasis.

Authors:  A Rothova; A van der Lelij; J S Stilma; W R Wilson; R F Barbe
Journal:  Lancet       Date:  1989-06-24       Impact factor: 79.321

Review 6.  Global data on blindness.

Authors:  B Thylefors; A D Négrel; R Pararajasegaram; K Y Dadzie
Journal:  Bull World Health Organ       Date:  1995       Impact factor: 9.408

7.  C-reactive protein and interleukin-6 are elevated in onchocerciasis patients after ivermectin treatment.

Authors:  F L Njoo; C E Hack; J Oosting; L Luyendijk; J S Stilma; A Kijlstra
Journal:  J Infect Dis       Date:  1994-09       Impact factor: 5.226

Review 8.  Angiotensin-converting enzyme and its clinical significance--a review.

Authors:  P R Studdy; R Lapworth; R Bird
Journal:  J Clin Pathol       Date:  1983-08       Impact factor: 3.411

9.  Serum angiotensin-converting enzyme activity in normal children and in those with sarcoidosis.

Authors:  G E Rodriguez; B C Shin; R S Abernathy; E L Kendig
Journal:  J Pediatr       Date:  1981-07       Impact factor: 4.406

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.